The clinical benefits of semaglutide (Wegovy; Novo Nordisk) in patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF) don’t appear to be influenced by left ...
Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...
Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Finerenone improved outcomes in patients with heart ...
LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...
The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...
MADRID, Spain—Two randomized, controlled trials testing beta-blockers in post-MI patients without heart failure or impaired left ventricular ejection fraction added a bit of confusion to a field ...
AstraZeneca’s SGLT2 diabetes drug Forxiga has another approval to celebrate. The drug, known as Farxiga in the U.S., gained a nod in Europe to treat patients suffering from heart failure with any type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback